The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
This it the RNS for me, that was a game changer just prior to the results.
Even RR had to start its recovery somewhere...
https://www.lse.co.uk/rns/OXB/update-on-cdmo-services-kkuod0ei8hi7occ.html
20 Mar 2024 07:00
RNS Number : 4894H
Oxford Biomedica PLC
20 March 2024
Oxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement
- New and expanded contracts highlight commercial momentum across all viral vector types
- OXB now working on multiple late-stage programmes with its portfolio of client programmes progressing to later stage work
Oxford, UK - 20, March, 2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica", "OXB" or "the Company"), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity.
Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services across all key viral vector types, with its portfolio of client programmes transitioning towards later stage work. As a result of commercial developments set out below, OXB is now working on three late-stage programmes.
Recently, the Company signed a contract with a new undisclosed US-based biotechnology company for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company's Oxford-based manufacturing facility.
Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing.
Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV).
Under the terms of these agreements, Oxford Biomedica will receive payments related to the development and manufacturing of viral vectors for use in clinical trials in addition to certain development and regulatory milestone payments. These payments will support the Company in achieving its medium-term financial guidance announced on 5 March 2024.
Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: "The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients' confidence in OXB's ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our c
ABL Europe could be buying shares of course
https://www.globenewswire.com/en/news-release/2024/01/29/2818732/0/en/Oxford-Biomedica-completes-acquisition-of-ABL-Europe.html
Chip stocks were big losers Wednesday. Blame disappointing results and guidance from semiconductor-equipment giant ASML (ASML), as well as caution ahead of Taiwan Semi's results.
AI chipmakers Nvidia, Broadcom (AVGO) and Arm Holdings (ARM) suffered significant to sharp losses Wednesday. As for chip-gear makers, ASML stock gapped lower, while Applied Materials (AMAT), Lam Research (LRCX), KLA Corp. (KLAC) broke key levels.
Gold trading back up to near record high at time of writing ( 8.15pm) - no real surprise, but the dips
https://tradingeconomics.com/commodity/gold